Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#2152 Sequential Therapies in Well-Differentiated Gastrointestinal Neuroendocrine Tumors G3 (NET G3): Platinum-Based vs. Platinum-Free Regimens

Introduction: Well-differentiated NET G3 show a longer clinical course than NEC G3, preliminary data indicate they respond poorly to platinum-based therapies.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Dal Buono A

Authors: Dal Buono A, Merola E, Delle Fave G, Wiedenmann B, Pavel M,

Keywords: well-differentiated, platinum, streptozotocin,

#1785 Eterogeneity of Duodenal Neuroendocrine Tumors: A Multi-Centre Experience in Italy

Introduction: Duodenal neuroendocrine neoplasms (dNENs) are heterogeneous tumors, which could have a highly variable prognosis.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Rossi, Roberta Elisa r

Authors: Massironi S, Panzuto F, Rinzivillo M, Rossi R, Delle Fave G,

Keywords: duodenal neuroendocrine neoplasm, duodenum, gastrinoma, somatostatinoma, diagnosis, therapy guidelines,

#1540 FOLFOX Chemotherapy: Efficacy and Tolerability in Advanced Digestive Neuroendocrine Neoplasms (NENs)

Introduction: FOLFOX has been poorly investigated in digestive NEN (DNENs), mostly in small cohorts.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Dal Buono A, Merola E, Delle Fave G, Wiedenmann B, Pavel M,

Keywords: FOLFOX, tolerability, tumor response.,

#1533 Chromogranin A in the Follow-up of Digestive Neuroendocrine Neoplasms: Is It a Useful Biomarker?

Introduction: Chromogranin A (CgA) is the most frequently used biomarker in digestive neuroendocrine neoplasms (DNENs) but its real usefulness is still unclear

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Merola E, Delle Fave G, Blankenstein O, Wiedenmann B, Pavel M,

Keywords: CgA, clinical usefulness, ≥ 50% increase,

#1437 Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: A Subgroup Analysis of the Phase 3 RADIANT-4 Study

Introduction: In the phase 3, RADIANT-4 study, everolimus (EVE) improved median progression-free survival (PFS) by 7.1 months in patients (pts) with advanced, progressive, nonfunctional NET of lung or GI tract compared to placebo (PBO); HR, 0.48; 95%CI, 0.35-0.67; P

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Fazio N

Authors: Fazio N, Buzzoni R, Delle Fave G, Tesselaar M, Wolin E,

Keywords: PFS, Everolimus, Lung carcinoid,